| pubmed-article:9468208 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0042373 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0004057 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0014792 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0678226 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0033414 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0439092 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0695347 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
| pubmed-article:9468208 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:9468208 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9468208 | pubmed:dateCreated | 1998-3-6 | lld:pubmed |
| pubmed-article:9468208 | pubmed:abstractText | Aspirin (acetylsalicylic acid, ASA) is widely used for secondary prevention of ischemic vascular events, although its protection only occurs in 25% of patients. We previously demonstrated that platelet reactivity is enhanced by a prothrombotic effect of erythrocytes in a thromboxane-independent manner. This diminishes the antithrombotic therapeutic potential of ASA. Recent data from our laboratory indicate that the prothrombotic effect of erythrocytes also contains an ASA-sensitive component. In accordance with this observation, intermittent treatment with high-dose ASA reduced the prothrombotic effects of erythrocytes ex vivo in healthy volunteers. In the present study, the effects of platelet-erythrocyte interactions were evaluated ex vivo in 82 patients with vascular disease: 62 patients with ischemic heart disease treated with 200 mg ASA/d and 20 patients with ischemic stroke treated with 300 mg ASA/d. | lld:pubmed |
| pubmed-article:9468208 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9468208 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9468208 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9468208 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9468208 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9468208 | pubmed:issn | 0009-7322 | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:MarcusA JAJ | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:SanchezEE | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:AznarJJ | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:LagoAA | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:BroekmanM JMJ | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:VallesJJ | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:SantosM TMT | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:HYT YTY | lld:pubmed |
| pubmed-article:9468208 | pubmed:author | pubmed-author:CosinJJ | lld:pubmed |
| pubmed-article:9468208 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9468208 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:9468208 | pubmed:volume | 97 | lld:pubmed |
| pubmed-article:9468208 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9468208 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9468208 | pubmed:pagination | 350-5 | lld:pubmed |
| pubmed-article:9468208 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:meshHeading | pubmed-meshheading:9468208-... | lld:pubmed |
| pubmed-article:9468208 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9468208 | pubmed:articleTitle | Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. | lld:pubmed |
| pubmed-article:9468208 | pubmed:affiliation | Research Center, University Hospital La Fe, Valencia, Spain. mteresas@san.gva.es | lld:pubmed |
| pubmed-article:9468208 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9468208 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9468208 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:9468208 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9468208 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9468208 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9468208 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9468208 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9468208 | lld:pubmed |
